Activated Charcoal Use in Chronic Kidney Disease Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Activated Charcoal, Phosphate Binders.
- Who it may be relevant to
- Registry conditions: End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients
Overview
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.
Interventions
- Drug Activated Charcoal
oral activated charcoal capsules - Drug Phosphate Binders
calcium-based or non-calcium based (sevelamer) binders
Primary outcome measures
- Serum phosphorus levels [Time frame: 8 weeks]
Secondary outcome measures (1)
- The percentage of patients who achieved decreasing at least 3 points in The Worst Itching Intensity Numerical Rating Scale (WI NRS) [Time frame: 8 weeks]
Eligibility criteria
Inclusion criteria
- Adult aged ≥18 years with ESRD.
- Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.
- Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).
Exclusion criteria
- Severely malnourished (as diagnosed by the department's dietitian).
- Treated with overnight dialysis.
- Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg/mL.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Double blind
- Primary purpose
- Treatment
Study locations
Egypt · 1 center
- Urology and Nephrology Center — Al Mansurah
Identifiers
NCT: NCT06906874 · 2024-117'2